The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
Elena Argento, Melissa Braschel, Zach Walsh, M Eugenia Socias, Kate Shannon
Journal of Psychopharmacology December 1, 2018 DOI: 10.1177/0269881118798610 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Prospective open cohort study Peer reviewed |
|---|---|
| Sample size | 340 |
| Population | Marginalized women in Vancouver, Canada, without suicidal ideation or attempt at baseline |
| Interventions | Psychedelics prescription opioids |
| Duration | Follow-up from 2010 to 2017 |
| Key findings | Psychedelic use moderated the association between prescription opioid use and suicide risk: prescription opioid use was associated with increased hazard of suicidal ideation or attempt among women who did not use psychedelics (hazard ratio 2.91) but not among those who did (hazard ratio 0.69), with the interaction remaining significant after adjustment. The authors argue this supports further research on psychedelics within trauma-informed interventions. |
Abstract
Background/aims: Given high rates of depression and suicide among marginalized women, and increasing calls to integrate trauma-informed biomedical and community-led structural interventions, this study longitudinally examines the potential moderating effect of psychedelic use on the relationship between other illicit drug use and suicide risk.
Methods: Data (2010–2017) were drawn from a community-based, prospective open cohort of marginalized women in Vancouver, Canada. Extended Cox regression analyses examined the moderating effect of psychedelic use on the association between other illicit drug use and incidence of suicidal ideation or attempt over follow-up.
Results: Of 340 women without suicidal ideation or attempt at baseline, 16% ( n=53) reported a first suicidal episode during follow-up, with an incidence density of 4.63 per 100 person-years (95% confidence interval 3.53–6.07). In unadjusted analysis, psychedelic use moderated the relationship between prescription opioid use and suicide risk: among women who did not use psychedelics, prescription opioid use increased the hazard of suicide (hazard ratio 2.91; 95% confidence interval 1.40–6.03) whereas prescription opioid use was not associated with increased suicidal ideation or attempt among those who used psychedelics (hazard ratio 0.69; 95% confidence interval 0.27–1.73) (interaction term p-value: 0.016). The moderating effect of psychedelics remained significant when adjusted for confounders (interaction term p-value: 0.036).
Conclusions: Psychedelic use had a protective moderating effect on the relationship between prescription opioid use and suicide risk. In the context of a severe public health crisis around prescription opioids and lack of addiction services tailored to marginalized women, this study supports calls for innovative, evidence-based and trauma-informed interventions, including further research on the potential benefits of psychedelics.
Citations in the library
Cited by 31
- People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences Drugs Education Prevention and Policy December 10, 2020
- Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential? Frontiers in Psychiatry July 19, 2021
- The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial Frontiers in Pharmacology November 19, 2019
- On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review ACS Pharmacology & Translational Science March 11, 2021
- Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Scientific Reports October 10, 2022
and 26 more in the library
Cites 38
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs Frontiers in Human Neuroscience 2014
and 33 more in the library